Equities analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report $19.60 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for BioDelivery Sciences International’s earnings. The highest sales estimate is $21.25 million and the lowest is $19.00 million. BioDelivery Sciences International posted sales of $11.28 million in the same quarter last year, which suggests a positive year over year growth rate of 73.8%. The business is scheduled to issue its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full year sales of $100.71 million for the current fiscal year, with estimates ranging from $98.60 million to $105.80 million. For the next fiscal year, analysts expect that the business will report sales of $141.39 million, with estimates ranging from $135.15 million to $149.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). BioDelivery Sciences International had a negative return on equity of 79.59% and a negative net margin of 60.87%. The firm had revenue of $18.03 million for the quarter, compared to analysts’ expectations of $16.15 million.
Shares of NASDAQ:BDSI traded down $0.34 during midday trading on Friday, reaching $4.51. 30,244 shares of the company traded hands, compared to its average volume of 1,096,591. The company has a debt-to-equity ratio of 1.74, a quick ratio of 2.82 and a current ratio of 3.07. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $5.37. The firm has a market cap of $341.28 million, a price-to-earnings ratio of -6.18 and a beta of 0.46.
In related news, Director Mark A. Sirgo sold 9,050 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $5.20, for a total transaction of $47,060.00. Following the transaction, the director now directly owns 2,509,005 shares of the company’s stock, valued at approximately $13,046,826. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $4.60, for a total value of $36,800.00. The disclosure for this sale can be found here. Insiders sold a total of 2,048,050 shares of company stock worth $10,241,990 over the last 90 days. Corporate insiders own 13.26% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Means Investment CO. Inc. purchased a new position in shares of BioDelivery Sciences International during the 1st quarter valued at about $59,000. Virtu Financial LLC purchased a new stake in BioDelivery Sciences International during the 1st quarter valued at about $300,000. Tibra Equities Europe Ltd purchased a new stake in BioDelivery Sciences International during the 1st quarter valued at about $727,000. Geode Capital Management LLC boosted its holdings in BioDelivery Sciences International by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock valued at $1,915,000 after acquiring an additional 5,628 shares during the period. Finally, Penn Capital Management Co. Inc. purchased a new stake in BioDelivery Sciences International during the 4th quarter valued at about $833,000. 57.09% of the stock is currently owned by institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Recommended Story: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.